公开(公告)号：US20230293430A1

公开(公告)日：2023-09-21

申请号：US18012110

申请日：2021-06-25

申请人： Mylan Pharma UK Limited

发明人： Jane Burrows ,  Gavin Magee ,  Claire Marcellin

IPC分类号： A61K9/00 ,  A61K31/397 ,  A61M15/00 ,  A61K47/26 ,  A61K31/137 ,  A61K31/567

CPC分类号： A61K9/0075 ,  A61K31/397 ,  A61M15/0003 ,  A61K47/26 ,  A61K31/137 ,  A61K31/567 ,  A61M2202/064

摘要： Powder formulations for use in dry powder inhalers and methods of making them are provided. A powder formulation can include from about 0.01% to about 90% by weight of a carboxamide compound comprising 5-[3-(3-Hydroxyphenoxy)azetidin-1-yl]-5-methyl-2,2-diphenyl-hexanamide or a pharmaceutically acceptable salt thereof and an excipient. Another powder formulation includes in addition to the carboxamide compound or its hydrochloride salt a long acting β2 adrenoreceptor agonist and an inhalable corticosteroid.

公开(公告)号：US20190192485A1

公开(公告)日：2019-06-27

申请号：US16325872

申请日：2017-08-21

申请人： MEREO BIOPHARMA 2 LIMITED

发明人： Jackie PARKIN ,  Lloyd B. KLICKSTEIN

IPC分类号： A61K31/4196 ,  A61K31/567 ,  A61P15/18 ,  A61K9/00 ,  A61K9/48 ,  A61P15/02

CPC分类号： A61K31/4196 ,  A61K9/0053 ,  A61K9/4866 ,  A61K31/567 ,  A61K45/06 ,  A61P15/02 ,  A61P15/18 ,  A61K2300/00

摘要： This invention relates to a dosage regimen comprising 4,4′-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile and a combined oral contraceptive for use in the treatment of endometriosis in a non-pregnant, pre-menopausal female. The invention also relates to a multi-phase combination preparation comprising 4,4′-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile and a combined oral contraceptive. The invention also relates to a kit comprising said multi-phase preparation and instructions for use.

公开(公告)号：US20190117671A1

公开(公告)日：2019-04-25

申请号：US16219496

申请日：2018-12-13

申请人： Corcept Therapeutics, Inc.

发明人： Joseph Belanoff ,  Coleman Gross

IPC分类号： A61K31/567 ,  G01N33/94 ,  A61K31/135 ,  A61K31/136 ,  A61K31/122

CPC分类号： A61K31/567 ,  A61K31/122 ,  A61K31/135 ,  A61K31/136 ,  G01N33/94 ,  G01N2800/048 ,  G01N2800/52

摘要： The present invention provides a method for optimizing levels of mifepristone in a patient suffering from Cushing's syndrome. The method comprises the steps of treating the patient with seven or more daily doses of mifepristone over a period of seven or more days; testing the serum levels of the patient to determine whether the blood levels of mifepristone are greater than 1631 ng/mL; and adjusting the daily dose of the patient to achieve mifepristone blood levels greater than 1631 ng/mL.

公开(公告)号：US20180325916A1

公开(公告)日：2018-11-15

申请号：US16045338

申请日：2018-07-25

申请人： Agile Therapeutics, Inc.

发明人： Charles G. ARNOLD ,  Agis Kydonieus ,  Thomas M. Rossi ,  Alfred F. Altomari

IPC分类号： A61K31/567 ,  A61K47/20 ,  A61K47/32 ,  A61K31/57 ,  A61K47/12 ,  A61K9/00 ,  A61K9/70

CPC分类号： A61K31/567 ,  A61K9/0014 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/57 ,  A61K47/12 ,  A61K47/20 ,  A61K47/32

摘要： A composition for transdermal delivery of a progestin for progestin hormone therapy is disclosed. Also disclosed is a transdermal delivery device comprising the composition. For progestin-only hormone therapy, the composition contains an anti-oxidant and does not contain an estrogen. For therapy involving a progestin and an estrogen, the composition contains the progestin, the estrogen and an additional anti-oxidant. Methods of improving the stability of progestin-containing compositions comprising oxidative agents are also disclosed. The methods comprise including one or more anti-oxidants in the compositions.

公开(公告)号：US20180221301A1

公开(公告)日：2018-08-09

申请号：US15945420

申请日：2018-04-04

申请人： MYLAN TECHNOLOGIES, INC.

发明人： Kristin Jackson ,  Kenneth J. Miller

IPC分类号： A61K9/70 ,  A61M37/00 ,  A61K31/567 ,  A61K31/565 ,  A61K9/00 ,  A61F13/00

CPC分类号： A61K9/7092 ,  A61F13/00 ,  A61F2013/00646 ,  A61F2013/00655 ,  A61F2013/0071 ,  A61F2013/00906 ,  A61K9/0014 ,  A61K9/7053 ,  A61K9/7061 ,  A61K31/565 ,  A61K31/567 ,  A61M37/00 ,  Y10T156/10

摘要： A transdermal drug-containing dosage unit comprises: a backing layer substantially impervious to the drug to be delivered transdermally; a first polymeric adhesive matrix, in contact with the backing layer, having dispersed therein the drug and having a first delivery profile of the drug; a second polymeric adhesive matrix, in contact with said first polymeric adhesive matrix, having dispersed therein the drug and having a second delivery profile of the drug, wherein said second delivery profile is different from said first delivery profile; and a release liner in contact with the second polymeric adhesive matrix.The first polymeric adhesive matrix can release the drug more quickly or more slowly than the second polymeric adhesive matrix. Through the selection of the two matrices, the delivery profile of the drug through the skin can be selectively modified and controlled.

公开(公告)号：US20180214558A1

公开(公告)日：2018-08-02

申请号：US15939415

申请日：2018-03-29

申请人： Foamix Pharmaceuticals Ltd.

发明人： Dov Tamarkin ,  Doron Friedman ,  Meir Eini

IPC分类号： A61K47/46 ,  A61K47/38 ,  A61K8/04 ,  A61K31/351 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/522 ,  A61K31/535 ,  A61K31/567 ,  A61K31/573 ,  A61K31/7036 ,  A61K31/7048 ,  A61K38/12 ,  A61K38/21 ,  A61K47/10 ,  A61K47/14 ,  A61K47/20 ,  A61K47/26 ,  A61K47/34 ,  A61K9/107 ,  A61K9/46 ,  A01N25/16 ,  A61Q19/04 ,  A61Q19/02 ,  A61Q17/04 ,  A61Q17/02 ,  A61Q7/02 ,  A61Q7/00 ,  A61K9/12 ,  A61K9/00 ,  A61K8/60 ,  A61K31/137

CPC分类号： A61K47/46 ,  A01N25/16 ,  A61K8/046 ,  A61K8/60 ,  A61K9/0007 ,  A61K9/0014 ,  A61K9/0034 ,  A61K9/107 ,  A61K9/12 ,  A61K9/122 ,  A61K31/137 ,  A61K31/351 ,  A61K31/4164 ,  A61K31/4174 ,  A61K31/522 ,  A61K31/535 ,  A61K31/567 ,  A61K31/573 ,  A61K31/7036 ,  A61K31/7048 ,  A61K38/12 ,  A61K38/212 ,  A61K47/10 ,  A61K47/14 ,  A61K47/20 ,  A61K47/26 ,  A61K47/34 ,  A61K47/38 ,  A61K2800/75 ,  A61Q7/00 ,  A61Q7/02 ,  A61Q17/02 ,  A61Q17/04 ,  A61Q19/02 ,  A61Q19/04

摘要： The invention relates to an alcohol-free cosmetic or pharmaceutical foam carrier comprising water, a hydrophobic solvent, a foam adjuvant agent, a surface-active agent and a water gelling agent. The cosmetic or pharmaceutical foam carrier does not contain aliphatic alcohols, making it non-irritating and non-drying. The alcohol-free foam carrier is suitable for inclusion of both water-soluble and oil soluble pharmaceutical and cosmetic agents.

公开(公告)号：US20180185387A1

公开(公告)日：2018-07-05

申请号：US15740763

申请日：2015-06-30

申请人： SHANGHAI JIAO TONG UNIVERSITY

发明人： Yongyong SHI ,  Zhijian SONG

IPC分类号： A61K31/567 ,  A61P35/00

CPC分类号： A61K31/567 ,  A61P35/00

摘要： This invention discloses applications of desogestrel in the preparation of anti-colon cancer/breast cancer ER-negative Ah receptor-positive products. This invention provides applications for desogestrel in the preparation of products to treat colon cancer and/or breast cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug desogestrel, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that desogestrel has a new use as an anti-colon cancer medication, thus achieving a new purpose for an old drug.

公开(公告)号：US09987288B2

公开(公告)日：2018-06-05

申请号：US15389833

申请日：2016-12-23

申请人： Mayo Foundation for Medical Education and Research

发明人： Allan B. Dietz ,  Peggy A. Bulur

IPC分类号： A61K31/567 ,  G01N33/569

CPC分类号： A61K31/567 ,  G01N33/56972 ,  G01N2333/70539 ,  G01N2333/70596

摘要： This document provides methods and materials involved in reducing suppression of immune function in mammals. For example, methods and materials for (a) identifying a mammal as having an elevated level of CD14+/DR− cells (e.g., CD14+/DR− monocytes) and (b) administering RU486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that change the ratio of CD14+/HLA-DR− cells to CD14+/HLA-DR+ cells as well as methods and materials for (a) identifying a mammal as being likely to experience an elevated level of CD14+/DR− cells (e.g., CD14+/DR− monocytes) and (b) administering RU486 (mifepristone; or drugs with a similar functional profile) to the identified mammal under conditions that reduce the degree to which the mammal develops CD14+/DR− cells are provided.

公开(公告)号：US09931305B2

公开(公告)日：2018-04-03

申请号：US15438458

申请日：2017-02-21

申请人： MonoSol Rx, LLC

发明人： Robert K. Yang ,  Richard C. Fuisz ,  Garry L. Myers ,  Joseph M. Fuisz

IPC分类号： A61K9/70 ,  A61K47/34 ,  A61K47/32 ,  A61K31/567 ,  A61K31/138 ,  A61K31/635 ,  A61K31/44 ,  A61K31/7048 ,  A61K31/4545 ,  A61K31/192 ,  A61K9/00 ,  A61K47/38

CPC分类号： A61K9/7007 ,  A61K9/0056 ,  A61K9/006 ,  A61K9/14 ,  A61K9/501 ,  A61K9/5015 ,  A61K9/5026 ,  A61K9/5036 ,  A61K9/5047 ,  A61K9/7015 ,  A61K31/138 ,  A61K31/192 ,  A61K31/422 ,  A61K31/44 ,  A61K31/4422 ,  A61K31/443 ,  A61K31/4545 ,  A61K31/519 ,  A61K31/549 ,  A61K31/567 ,  A61K31/635 ,  A61K31/704 ,  A61K31/7048 ,  A61K47/02 ,  A61K47/10 ,  A61K47/22 ,  A61K47/32 ,  A61K47/34 ,  A61K47/36 ,  A61K47/38 ,  A61K47/44 ,  A61K47/46 ,  B05D3/0254 ,  B29C47/0004

摘要： The present invention relates to rapid dissolve thin film drug delivery compositions for the oral administration of active components. The active components are provided as taste-masked or controlled-release coated particles uniformly distributed throughout the film composition. The compositions may be formed by wet casting methods, where the film is cast and controllably dried, or alternatively by an extrusion method.

公开(公告)号：US20180085305A1

公开(公告)日：2018-03-29

申请号：US15720921

申请日：2017-09-29

申请人： Gesea Biosciences Inc.

发明人： John H. BAILLIE ,  Ruth BAILLIE ,  George BLOUIN ,  Newsha FARAHANI ,  Christopher MARX

IPC分类号： A61K9/00 ,  A61K31/57 ,  A61K47/24 ,  A61K47/28 ,  A61K47/10 ,  A61K47/12 ,  A61K31/192 ,  A61K31/325 ,  A61K31/593 ,  A61K31/167

CPC分类号： A61F6/08 ,  A61F6/22 ,  A61F2002/30677 ,  A61K9/0002 ,  A61K9/0024 ,  A61K9/5021 ,  A61K31/167 ,  A61K31/192 ,  A61K31/325 ,  A61K31/567 ,  A61K31/57 ,  A61K31/593 ,  A61K47/10 ,  A61K47/12 ,  A61K47/24 ,  A61K47/28 ,  A61K47/36 ,  A61L27/54 ,  A61L27/58 ,  A61L2300/404

摘要： A drug delivery system is provided in the form of a controlled release, bioerodible pellet for subdermal implantation. The pellet is bioerodible, and provides for the sustained release of a pharmacologically active agent over an extended time period. As such, the drug delivery system finds significant utility in chronic drug administration. Bioerosion products are water soluble, bioresorbed, or both, obviating the need for surgical removal of the implant. Methods for manufacturing and using the drug delivery system are also provided.